Stroke Pharmacogenomics and Genetics

This is a multidisciplinary group composed of 17 members, including biologists, psychologists, biotechnologists, and neurologists. The objectives of the group are to find treatments for stroke and other neurological diseases that can be used in clinical practice. To find these treatments, we are using genome-wide techniques such as GWAS, EWAS, TWAS, PWAS, or microbiome analysis. This includes genetics, epigenetics, transcriptomics, proteomics, and microbiomics with large cohorts of patients.

Main Lines of Research

• Genetic risk factors in stroke. (Carcel Marquez, Jara).
• Pharmacogenetics of neurovascular diseases. (Fernandez Cadenas, Israel).
• Genetic and epigenetic risk factors associated with the neurological deterioration and the disability after stroke. (Gallego Fabrega, Cristina; Cullell Fornes, Natalia).
• Genetic, epigenetic, and proteomic factors associated with the endophenotypes of the acute phase of stroke. Integromics. (Fernandez Cadenas, Israel).
• Microbiome and Stroke. (Fernandez Cadenas, Israel).
• Lipids and Stroke. (Martin Campos, Jesus Maria).
• CADASIL and other neurological diseases. (Muiño Acuña, Elena).

Scientific Challenges

• Integration of multi-omic data to find the key drivers associated with stroke risk and outcome.
• To locate drug targets and treatments in stroke risk and outcome using bioinformatic and AI analysis.
• To understand the biological mechanisms of stroke and other neurological pathologies.
• To find treatments for CADASIL, a rare disease that causes vascular dementia and stroke.

Contact

Fernández-Cadenas, Israel
IFernandezC@santpau.cat